Companies › Paradigm Biopharmaceuticals
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 3; Immunology; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Pentosan Polysulfate Sodium Glycosaminoglycan polysulfate with anti-inflammatory and anti-thrombotic properties | – | Phase 3 | Osteoarthritis, Knee | Jul 2027 |
| Pentosan Polysulfate Sodium Glycosaminoglycan polysulfate; anticoagulant and fibrinolytic agent with potential cartila | – | Phase 2 | Osteoarthritis, Knee | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04809376 | Pentosan Polysulfate Sodium | Phase 2 | Osteoarthritis, Knee | Immunology | Oct 2024 |
| NCT06917404 | Pentosan Polysulfate Sodium | Phase 3 | Osteoarthritis, Knee | Immunology | Jul 2027 |
No annotated target.
–
Arthrosi Therapeutics Prime Gene Therapeutics Citryll Toll Biotech Co. Ltd. (Beijing) Ventus Therapeutics U.S.
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.